Gastrointestinal drugs
By
Mwengei
BSc N & PH
,1. PEPTIC ULCER
DISEASE
BY
MWENGEI
,1. PEPTIC ULCER DISEASE
Acid peptic disease includes:
•Peptic ulcers (gastric ulcer, duodenal ulcer , NSAIDS induced u
•Gastro-esophageal reflux disease
•Bacterial induced – H-pyroli
• Hyper secretory states like Zollinger Ellison Syndrome (ulcero
tumour of the islets of Langerhans.
Principles of therapy
The aim of therapy is to;
❖ Relieve symptoms,
❖ Induced ulcer healing and cure in the long run
❖ Decreased risk of complications
❖ Stopping reoccurrence .
, Classification Of Agents Used in Treatment of Peptic U
Inhibition Of Acid Secretion
H2 receptor antagonist e.g. cimetidine, ranitidine, famotidine
roxatidine.
Proton pump inhibitors e.g. omeprazole, pantoprazole, esomepr
lansoprazole.
Anticholinergics e.g. pirenzepine.
Prostaglandin analogue e.g. misoprostol.
Neutralization of gastric acids
Sodium bicarbonate systemic
Non systemic: magnesium hydroxide, aluminium hydroxide,
magnesium trisilicate.
By
Mwengei
BSc N & PH
,1. PEPTIC ULCER
DISEASE
BY
MWENGEI
,1. PEPTIC ULCER DISEASE
Acid peptic disease includes:
•Peptic ulcers (gastric ulcer, duodenal ulcer , NSAIDS induced u
•Gastro-esophageal reflux disease
•Bacterial induced – H-pyroli
• Hyper secretory states like Zollinger Ellison Syndrome (ulcero
tumour of the islets of Langerhans.
Principles of therapy
The aim of therapy is to;
❖ Relieve symptoms,
❖ Induced ulcer healing and cure in the long run
❖ Decreased risk of complications
❖ Stopping reoccurrence .
, Classification Of Agents Used in Treatment of Peptic U
Inhibition Of Acid Secretion
H2 receptor antagonist e.g. cimetidine, ranitidine, famotidine
roxatidine.
Proton pump inhibitors e.g. omeprazole, pantoprazole, esomepr
lansoprazole.
Anticholinergics e.g. pirenzepine.
Prostaglandin analogue e.g. misoprostol.
Neutralization of gastric acids
Sodium bicarbonate systemic
Non systemic: magnesium hydroxide, aluminium hydroxide,
magnesium trisilicate.
